ERBB2 and non-small cell lung carcinoma: Even if mono-immunotherapy is the only approved option in PD-L1 overexpressing NSCLC and no anti-HER2 agent is available in Italy, the molecular portrait of this never-smoker patient led us to choose front-line chemoimmunotherapy.